본문 바로가기
KERD
논문KCI 등재

흰쥐에서 나린진이 타목시펜의 약물동태에 미치는 영향

Effect of Naringin on Tamoxifen Pharmacokinetics in Rats

최인|김형석|최준식
한국임상약학회 (Korean College Of Clinical Pharmacy)|2005.06|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제15권 제1호|pp. 55-60

0

조회

0

다운로드

0

인용

0

참고문헌

주제분류약학

초록

Abstract

The aim of this study is to investigate the effect of naringin on the pharmacokinetics of tamoxifen in rats. Tamoxifen (10 mg/kg) was administered orally 0.5 h and 3 days after oral administration of naringin (5 mg/kg). The plasma concentrations of tamoxifen were increased significantly by naringin compared to control. Absorption rate constant (Ka) of tamoxifen with naringin was increased significantly compared to that of the control. The areas under the plasma concentration-time curve (AUC) and the peak concentrations (Cmax) of tamoxifen with naringin were significantly higher than those of the control. Consequently, the relative bioavailability (R.B%) of tamoxifen with naringin was 2-3-fold higher than the control, and absolute bioavailability (A.B%) of tamoxifen were significantly higher (p<0.05 with coadministration,p<0.01 with pretreatment) than those of the control. The increased bioavailability of tamoxifen in rats with naringin might be associated with the inhibition by naringin of an efflux pump P-glycoprotein and the first-pass metabolizing enzyme CYP3A4.

참고문헌 (39)

  1. Powles, "The case for clinical trials of tamoxifen forprevention of breast cancer", pp.1145~1147 (1992)
  2. I, "Use of tamoxifen for breast cancer", pp.513~529 (1995)
  3. Lim, "A comparative study of tamoxifenmetabolism in female rat", carci(genesis), pp.589~593 (1994)
  4. Mani, "Metabolism of the antimammary cancerantiestrogenic agent tamoxifen", pp.645~656 (1993)
  5. Mani, "Involvement of cytochrome P4503A in catalysis of tamoxifenactivation and covalent binding to rat and human livermicrosomes", carci(genesis), pp.2715~2720 (1994)
  6. Kangas, "Involvement of cytochrome P4503A enzyme family in the major metabolic pathways oftoremifene in human liver microsomes", drea
  7. Kupfer, "Cytochrome P-450 3A and2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifenand 3-hydroxytamoxifen involvement of catechols in covalent binding tohepatic proteins", 27, pp.681~688 (1999)
  8. Mani, "Metabolism of the antimammary cancerantiestrogenic agent tamoxifen", pp.645~656 (1993)
  9. Crewe, "Variable contribution of cytochromes P450 2D6 2C9 and3A4 to the 4-hydroxylation of tamoxifen by human livermicrosomes", 53, pp.171~178 (1997)
  10. Daniel, "Determination of tamoxifen and biologicallyactive metabolites in human breast tumour and plasma", pp.1183~1189 (1981)
  11. Jordan, "A monohydroxylated metabolite of tamoxifen with potentantioestrogenic activity", endocri(l), pp.305~316 (1977)
  12. DeGregorio, "Tumor and serum tamoxifen concentrations in the athymicnude mice", pp.68~70 (1989)
  13. Robinson, "Implications of tamoxifen metabolism in the athymicmouse for the study of antitumor effects upon human breastcancer xenografts", pp.1769~1776 (1989)
  14. Gant, "In vivo induction of liver P-glycoproteinexpression by xenobiotics in monkeys", 133, pp.269~276 (1995)
  15. U, "substrates of the human Pglycoprotein", pp.287~292 (1994)
  16. Berman, "Effect of tamoxifenon cell lines displaying the multidrug-resistant phenotype", pp.818~825 (1991)
  17. Jacobson, "Effect of tamoxifen on themultidrug-resistant phenotype in human breast cancercells", pp.441~447 (1994)
  18. Hamada, "Cellular localization of themultidrug-resistance gene product P-glycoprotein in normalhuman tissues", pp.7735~7738 (1987)
  19. O'Brien, "is expressedby endothelial cells at blood-brain barrier sites", pp.695~698 (1989)
  20. I, "Tissue distribution of Pglycoproteinencoded by a multidrug-resistant gene asrevealed by a monoclonal antibody", pp.~16
  21. Gottesman, "Biochemistry of multidrugresistance mediated by the multidrug transporter", pp.385~427 (1993)
  22. Gan, "CYP3ALikecytochrome P450-mediated metabolism and polarizedefflux of cyclosporin A in Caco-2 cells interactionbetween the two biochemical barriers to intestinal transport", pp.344~349 (1996)
  23. Watkins, "The barrier function of CYP3A4 and Pglycoproteinin the small bowel", 27, pp.161~170 (1996)
  24. A, "Role of P-glycoprotein and cytochrome P450 3A in limitingoral absorption of peptides and peptidomimetics", pp.1322~1330 (1998)
  25. Ito, "Effects of intestinalCYP3A4 and P-glycoprotein on oral drug absorptiontheoretical approach", 16, pp.225~231 (1999)
  26. Miller, "P-glycoprotein expression inmalignant lymphoma and reversal of clinical drug resistancewith chemotherapy plus high-dose verapamil", pp.17~24 (1991)
  27. Wishart, "Adequate tumour quinidine levels formultidrug resistance modulation can be achieved in vivo", pp.28~31 (1992)
  28. A, "PhaseI", II trial of cyclosporine as a chemotherapy-resistance modifierin acute leukemia, 1993, 1652~1660
  29. A, "Flavonoids and isoflavonoidsgoldmine for metabolic engineering", pp.394~400 (1999)
  30. van Nood, "a review of probable mechanisms of action andpotential applications", flavo(ids), pp.418~425 (2001)
  31. Burke, "selective substrates and inhibitors for cytochrome P450CYP1A and CYP1B1", bioflavo(ids), pp.31~38 (2000)
  32. Dupuy, "Enhancement of moxidectin bioavailability inlamb by a natural flavonoid", 112, pp.337~347 (2003)
  33. A, "Increased oral bioavailability of paclitaxel by GF120918in mice through selective modulation of P-glycoprotein", (oijen), pp.4416~4421 (2000)
  34. Kim, "Intestinal bacterial metabolism of flavonoidsand its relation to some biological activities", pp.17~23 (1998)
  35. Zhang, "Effect of the grapefruit flavonoid naringin on pharmacokineticsof quinine in rats", 17, pp.351~363 (2000)
  36. Ho, "Inhibition ofhuman CYP3A4 activity by grapefruit flavonoids", fura(coumarinsand related compounds), pp.217~27 (2001)
  37. A, "Inhibition of vinblastine efflux mediated by P-glycoproteinby grapefruit juice components in caco-2 cells", 21, pp.1062~1066 (1998)
  38. A, "Inhibition of theCYP3A4-mediated metabolism and P-glycoprotein-mediatedtransport of the HIV-1 protease inhibitor saquinavirby grapefruit juice components", 48, pp.543~552 (1999)
  39. Fried, "Direct determination oftamoxifen and its four major metabolites in plasma usingcoupled column high-performance liquid chromatography", pp.261~268 (1994)

관련 논문AI추천

나린제닌과 딜티아젬과의 약물동태학적 상호작용설효찬, 최준식한국임상약학회 · 한국임상약학회지2006 · 제16권 제1호토끼에서 나린진이 니모디핀의 생체이용률에 미치는 영향김현용, 이준한, 최준식한국임상약학회 · 한국임상약학회지2008 · 제18권 제2호Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration곽민아, 구세광, 박성환, 박수진, 이영준대한예방한의학회 · 대한예방한의학회지2016 · 제20권 제2호Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen구세광, 김주익, 이영준한의병리학회 · 동의생리병리학회지2020 · 제34권 제4호Effects of Apigenin, an Antioxidant, on the Bioavailability and Pharmacokinetics of Etoposide박선희, 임태환, 최준식한국임상약학회 · 한국임상약학회지2011 · 제21권 제2호

이 간행물의 다른 논문 (9건)

Clopidogrel 약물 상호 작용이 심혈관계 질환 예방 효과 및 부작용에 미치는 영향김성희, 이숙향pp. 1-8소아 총정맥영양의 간담도계 합병증에 대한 Ursodeoxycholic acid의 예방효과에 대한 연구민명숙, 손기호, 백남선, 이숙향, 박태성, 김지희, 최경업, 인용원, 최연호pp. 9-20개선된 HPLC분석법을 이용한 세파클러 모노하이드레이트 250 mg 캡슐의 생물학적동등성한선영, 이범진, 김태완, 강성하, 신관석, Cao, Qing-Ri, 송옥경pp. 21-27소아입원환자에서의 약물사용 평가박광준, 신완균, 신은정, 하헌주pp. 27-33식단에 따르는 페노피브레이트 서방성 캡슐의 1회 경구 투여 후 약물동태학 및 약물동력학의 평가최선옥, 김형기, 정수연, 이은주, 김정현, 윤휘열, 강원구, 권준택, 권광일pp. 34-40
원문 보기